BRIEF-J&J Says FDA Approves Label Expansion, Cementing Tremfya As The Only Il‑23 Inhibitor Proven To Help Stop Further Joint Damage

Johnson & Johnson

Johnson & Johnson

JNJ

0.00

May 28 (Reuters) - Johnson & Johnson JNJ.N:

  • FDA APPROVES LABEL EXPANSION, CEMENTING TREMFYA® AS THE ONLY IL‑23 INHIBITOR PROVEN TO HELP STOP FURTHER JOINT DAMAGE

  • J&J - TREMFYA SHOWS SIGNIFICANT INHIBITION OF STRUCTURAL JOINT DAMAGE IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

  • J&J - TREMFYA ONLY IL-23 INHIBITOR PROVEN TO STOP FURTHER STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS

  • J&J - APEX STUDY SHOWS NO NEW SAFETY SIGNALS FOR TREMFYA

Source text: ID:nPnbj3Jhqa

Further company coverage: JNJ.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.